ENFIN! Computational systems biology comes to a lab bench near you
The Commission of the European Union has awarded EUR 9 million over five years for a new Network of Excellence that will make computational systems biology accessible to bench scientists throughout Europe and beyond. ENFIN, which stands for ‘Experimental Network for Functional INtegration,’ brings together some of Europe’s best computational and experimental biology labs – 20 groups across 17 institutions in 13 countries – to build a virtual institute that will put Europe at the centre of the systems biology revolution.
Genome sequencing and other high-throughput technologies have triggered a renaissance in computational biology: there’s now a large, open-access database for almost every type of biological information. Yet the average biologist at the lab bench uses only a tiny proportion of the information that is relevant to the questions s/he is trying to answer. Why is this? “To the bench scientist, computational biology is like driving around an unfamiliar city: you might be able to see your hotel, but finding your way to the car park through the oneway system can be a nightmare,” explains the EMBLÐEuropean Bioinformatics Institute’s Ewan Birney, who will coordinate ENFIN. “ENFIN will revise the town plan so that frustrating one-way system no longer exists: researchers will be able to go straight to the public data that they want, combine it with their own unpublished data and perform truly integrated analyses using data from different types of experiments.”
Birney and the ENFIN executive committee (see notes for editors) will work with project managers whose expertise spans database architecture (e.g. Henning Hermjakob, EMBL-EBI; Geoff Barton, University of Dundee) data analysis tools (e.g. Søren Brunak, Technical University of Denmark; Eran Segal, Weizmann Institute) and experimental molecular biology (e.g. Carl-Henrick Heldin, Ludwig Institute for Cancer Research, Uppsala; Erich Nigg, Max-Planck Institute for Biochemistry, Martinsried) to create the next generation of informatics resources for systems biology.
ENFIN’s products will be applicable to any area of biological research, but a strong experimental focus of the network is understanding the regulation of cell division; this process is deregulated in many diseases, most notably cancer. By applying ENFIN’s methods to this important area of biomedical research, ENFIN will contribute directly to the understanding of disease, in addition to making a significant indirect contribution by making the ENFIN infrastructure freely available to researchers across the globe.
By combining the expertise of both ‘wet’ and ‘dry’ biologists, ENFIN will catalyse a social change in which computational approaches will be incorporated into the molecular biologist’s tool set and will no longer be regarded as the domain of the bioinformatician alone. “Only once we can make databases and algorithms as commonplace as pipettes and cell culture will we be in a position to realise the full potential of molecular biology in this new data-intensive world,” concludes Birney.
European Molecular Biology Laboratory Ewan Birney* (coordinator), EMBL-European Bioinformatics Institute, Hinxton, UK Jan Ellenberg, EMBL Heidelberg, Germany Henning Hermjakob, EMBL-European Bioinformatics Institute, Hinxton, UK
University of Dundee, Scotland, UK Geoffrey J. Barton
Technical University of Denmark Søren Brunak
University of Rome Tor Vergata, Italy Gianni Cesareni*
Medical Research Council Mammalian Genetics Unit, Harwell, UK John Hancock
Ludwig Institute for Cancer Research, Uppsala, Sweden Carl-Henrik Heldin*
Max Planck Institute of Biochemistry, Martinsried, Germany Edda Klipp Erich Nigg
University of Helsinki, Finland Tomi Mäkelä
University College London, UK Christine Orengo*
National Center for Research and Technology, Greece Christos Ouzounis
National Consortium for Genomics Research, France Vincent Schachter*
University of Cologne, Germany Dietmar Schomburg
Weizmann Institute, Rehovot, Israel Eran Segal
Egeen, Estonia Jaak Vilo
Serono Pharmaceutical Research Institute, Switzerland Ioannis Xenarios
Consejo Superior de Investigaciones Cient’ficas, Madrid, Spain Alfonso Valencia
Centre for Integrative Bioinformatics VU, Amsterdam, The Netherlands Jaap Heringa
To study the effect of commonly used drugs on bacterial envelopes, EMBL scientists applied a biochemical assay using a colour reaction. The deeper the red, the stronger the disruptive effect of the drug.